Kymera Therapeutics KYMR Other Nonoperating Expense
Other Nonoperating Expense at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingExpense.
The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kymera Therapeutics's other nonoperating expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kymera Therapeutics's other nonoperating expense?
- Kymera Therapeutics (KYMR) reported other nonoperating expense of $61K in Q1 2026.
- How has Kymera Therapeutics's other nonoperating expense changed year-over-year?
- Kymera Therapeutics's other nonoperating expense decreased by 15.3% year-over-year, from $72K to $61K.
- What is the long-term trend for Kymera Therapeutics's other nonoperating expense?
- Over 4 years (2021 to 2025), Kymera Therapeutics's other nonoperating expense has grown at a 20.8% compound annual growth rate (CAGR), from $173K to $368K.
- What does other nonoperating expense mean?
- This metric captures costs incurred that are not directly related to the primary business operations, including interest expense on debt, losses on asset disposals, or other non-recurring financial charges. It reflects the cost of capital and the impact of peripheral financial obligations on the company's net earnings. Tracking this helps investors assess the burden of non-operational liabilities and financial leverage on the firm's profitability.